Live Breaking News & Updates on Compelling Investment Opportunitymonday

Needham upgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Hold to Buy, with a price target of $155. The price target, according to the firm, is based on 25 times its estimated earnings per share for 2022, discounted 20 percent annually.
Analysts Alan Carr and Danielle. Read More.
Don t Miss Any Updates!
News Directly in Your Inbox
Subscribe to: ....

Eun Yang , Danielle Brill , Cory Kasimov , Alan Carr , Epidiolex Resultstuesday , Keros Therapeutics Inc , Drug Administration , Gw Pharmaceuticals , Vertex Pharmaceuticals Incorporated , Reasons Vertex Pharmaceuticals Just Got Upgradedfriday , Acceleron Pharma Inc , Pharmaceuticals Inc , Piper Jaffray , Analyst Color , Pharma Analysts Are Bracing For , Nuplazid In Dementiatuesday , Compelling Investment Opportunitymonday , Therapeutics Inc , Positive Earnings , Piper Jaffray Says In Upgradefriday , Pharma Inc , Analyst Danielle Brill , Long Ideas , Vertex Pharmaceuticals Just Got Upgradedfriday , ஏன் யாங் , டேனியல் புல் ,